Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

99m-Tc-Bleomycin is a promising tool for scintigraphic imaging of some types of malignant tumours. The rapid decay of 99m-Tc, together with a high affinity of bleomycin for certain histologically-defined tumours recommends its use in humans. Moreover, by using high specific activities of bleomycin, no toxic effects are to be expected. At 00-C, the chelate of 99m-Tc and bleomycin is stable and its storage or transport are recommended at this temperature. Following the i.v. injection of rats with 99m-Tc-bleomycin, a high specific activity is found in the liver, spleen, lungs and skin. In view of its excretion by the kidneys an extremely high activity is found in the urogenital system. Scintigraphic imaging of lymph nodes in a case of Hodgkin's disease, of a embryonal carcinoma, of a thyroid carcinoma, of an astrocytoma and of a solid carcinoma was obtained in patients investigated by this method.
 ...
PMID:Bleomycin as carrier substance for 99m-Technetium in tumour diagnosis (author's transl). 4 33

The number of lymphocytes forming spontaneous rosettes with sheep erythrocytes, a property of thymus-dependent (T) cells, and the number of lymphocytes bearing surface immunoglobulins, a characteristic feature of bone marrow-dependent (B) cells, were determined in the peripheral blood of normals and of patients with chronic lymphocytic leukemia (CLL) and Hodgkin's disease. As compared with normal individuals CLL patients had an increased percentage of lymphocytes with membrane-bound immunoglobulins, whereas the proportion of rosette-forming lymphocytes was reduced. In Hodgkin's disease either normal, diminished, or increased B cell values were obtained; the percentage of T cells was decreased or within the lower range of normals. Lymphocyte transformation by various mitogenic agents in vitro may be regarded as a model of lymphocyte reactivity during immunologic processes in vivo. In order to study the functional capacity of lymphocytes in CLL and Hodgkin's disease in comparison with normal cells, purified peripheral blood lymphocytes from normals and patients with these diseases were incubated in vitro with phytohemagglutinin (PHA) and pokeweed mitogen (PWM) over 7 to 11 days. DNA synthesis was determined by incorporation of 3-H-thymidine. The cyto-architectural features of the cells before and during incubation with these phytomitogens were studied by electron microscopy. Planimetric measurements were performed on micrographs of comparable cell sections (through nucleus and Golgi zone) for the determiniation of cell, nuclear, cytoplasmic, and mitochondrial area. Furthermore, the number of mitochondria and of membrane-bounded acid phosphatase-positive lysosome-like organelles was determined in comparable sections of unstimulated and mitogen transformed lymphocytes.
 ...
PMID:[T and B lymphocytes in chronic lymphocytic leukemia and Hodgkin's disease. Electron microscopic and immunologic studies]. 4 38

Haematological cytopenias caused by increased splenic activity occurred in 86 patients with malignant lymphomas (50 patients with stage III or IV Hodgkin disease [H.D.] and 36 with non-Hodgkin lymphomas). Splenectomy was performed in 84 of these 86 patients. There was complete or partial correction of the haematological defect in 90% of the H.D. patients and 89% of the non-Hodgkin patients. Chemotherapy or radiotherapy was started after the haematological defect had been corrected by splenectomy, and as a result 79% of the H.D. patients and 75% of the non-Hodgkin patients had a complete or partial remission of their disease. Increased splenic activity should be considered as a cause of a haematological cytopenia in patients with malignant lymphomas even in those with bone-marrow involvement, since splenectomy is accompanied by excellent results in terms of disease remission with subsequent therapy. 2 patients with H.D. (4%) and 5 with non-Hodgkin lymphomas (14%) died in hospital after splenectomy. Thus the operation was associated with acceptable mortality and morbidity despite the advanced stage of disease in most cases.
 ...
PMID:Splenectomy for haematological cytopenias in patients with malignant lymphomas. 4 99

Iodine-131-labeled immunospecific gamma globulin derived from immunization of rabbits with F antigen, a tumor associated antogen in Hodgkin's disease, has been utilized for intralymphatic infusion in a patient with known recurrent Hodgkin's disease inthe inguinofemoral and pelvic regions. Rectilinear scanning successfully delineatedthe tumor masses, and external monitoring showed retention of activity in the tumor sitesover an 8-day period.
 ...
PMID:Radionuclide immunoglobulin lymphangiography: a case report. 5 Jan 21

The monocytes of 7 patients with advanced Hdgkin's disease (stages III and IV) and of two patients with generalized lymphosarcoma exhibited a highly significant impairment of the phagocytosis of IgG-coated red cells, regardless of receiving therapy or not. In contrast three patients with M. Hodgkin, stage II B, and one with lymphosarcoma in complete remission showed a rather elevated monocyte phagocytic acitivity. The nitroblue tetrazolium reduction by monocytes in the mean was significantly enhanced in all patients investigated, compared with normal persons, although only in one patient a bacterial infection was apparent at the time of the test. The possible implication of the findings in the well known immunodeficiency present in M. Hodgkin and lymphosarcoma is discussed.
 ...
PMID:Reduced monocyte phagocytosis in patients with advanced Hodgkin's disease and lymphosarcoma. 5 Apr 73

In the majority of patients with lympho- and reticulum cell sarcomas, high numbers of B-lymphocytes were found in affected lymph nodes, but were rarely observed in the peripheral blood. In chronic lymphocytic leukaemia receptor properties of B-lymphocytes were defective in several aspects. In patients with Hodgkin's disease the relative number of both lymphocyte populations in the blood were within the normal range and in lymph node suspensions marked alterations were unusual. A preferential proliferation of T-lymphocytes, perhaps accompanied by a reduced life span, was however suggested by double labelling experiments.
 ...
PMID:Classification of malignant lymphomas by means of membrane markers. 5 Jul 9

The studies of skin sensitivity, the reactivity to intradermally transferred lymphocytes and lymphocytic transformation in vitro showed that delayed hypersensitivity had been slightly impaired in patients with Hodgkin's disease during long time remission. The regression of the disease favoured the recovery of the lymphocytic functions and the delayed type immune reactions associated with them. These data suggest that the enhancement of the delayed hypersensitivity of the tumour defence respectively could promote the treatment or prevention of the disease.
 ...
PMID:Studies on delayed hypersensitivity of patients with Hodgkin's disease during remission. 5 Sep 67

Progress in the chemotherapy of Hodgkin's disease and experimental therapeutic, pharmacologic, and clinical studies of the antitumor antibiotic, adriamycin, are presented in this abstract. In patients with disseminated Hodgkin's disease, the combination chemotherapy program (MOPP) produces a significant increase in the complete remission rate. This has been increased to 90% by the addition of low dose bleomycin to the MOPP program. The continuation of MOPP treatment beyond 6 months and to a total of 24 months provides improved results in patients in remission as measured either from time of onset of complete remission or from end of treatment. Finally, the pattern of relapse in patients with Hodgkin's disease provides a rationale basis for the selective use of radiotherapy in patients in complete remission. Adriamycin has a broad spectrum of antitumor activity in man. Its mechanism of action involves intercalation with DNA and inhibition of DNA function. The selective effect against tumors is not understood but may relate to membrane transport. Adriamycin is a highly important new antitumor agent for the treatment, not only of hematologic malignancies, but for a variety of solid tumors as well.
 ...
PMID:Progress in the chemotherapy of hematologic diseases. 5 22

DNA-RNA hybridization was used to explore whether human neoplasias contain RNA molecules having sequence homologies to those of the RNA tumor viruses known to cause similar diseases in animals. The pattern of specific RNAs found in the human tumors showed a remarkable concordance with the predictions deducible from the animal systems. Thus human breast cancer contains RNA homologous only to that of the murine mammary tumor virus (MMTV). Human leukemias, sarcomas, and lymphomas (including Hodgkin's and Burkitt's) all contain RNA with sequence homology to the murine leukemia virus (RLV) and not to MMTV RNA. Finally, as in the case of the mouse, none of the human tumors examined contain RNA related in sequence to that of the avian myeloblastosis virus (AMV). The RNA detected in all of the human neoplasias was demonstrated to be of high molecular weight (1 times 10(7) daltons) and encapsulated with a reverse transcriptase in particles having densities between 1.16-1.19 g/ml. Further, the RNA of these human tumor particles was related in sequence to the murine viruses that cause the corresponding neoplasias in mice. Thus, 4 features diagnostic for the murine oncogenic viruses are satisfied by the particles found in the human cancers. Finally, it was shown by "recycling" experiments that the DNA from human leukemic cells and from lymphomatous tissue contained particle-related sequences that could not be detected in normal DNA. This finding was further substantiated by studies with identical twins in which it was shown that the leukemic twin contained particle-related sequences that could not be detected in the leukocytes of his identical healthy sibling. These findings are inconsistent with hypotheses that require chromosomal transmission in the germ line of complete copies of the information required to produce malignancy and the associated virus particles.
 ...
PMID:Sequences related to the RNA tumor viruses in the RNA and DNA of human leukemias and lymphomas. 5 26

The results obtained with intensive chemotherapy and intensive chemotherapy plus radiotherapy in non-Hodgkin's lymphomata are reported. A quintuple drug regimen (mechloretamine, adriamycin, bleomycin, vincristine and prednisone) in histiocytic lymphomata (Stage III and IV) yielded complete remissions in 53% and complete plus partial remissions in 77%. These figures were 44% and 64% respectively in lymphocytic lymphoma. In Stage III complete responders after combination chemotherapy were subsequently irradiated (involved field irradiation). The median duration of complete remission after completion of radiotherapy was 9-5 months in histiocytic and 12-0 months in lymphocytic lymphomata. At 2 years actuarial survival in Stage III and IV was better in patients with the lymphocytic type and with nodular pattern than with histiocytic and diffuse patterns. A more recent trial compares, in Stage IV patients, cyclophosphamide, vincristine and prednisone (CVP) versus adriamycin, bleomycin and prednisone (ABP). Although the number of evaluable patients is still limited, there appears to be no difference in the response rate between CVP and ABP. In Stages I and II, 6 cycles of CVP were given as adjuvant treatment after radiotherapy. At the present moment, there is no statistical difference in the relapse rate between the group of patients treated with radiotherapy alone and that with radiotherapy plus CVP.
 ...
PMID:Combination chemotherapy and radiotherapy in non-Hodgkin's lymphomata. 5 67


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>